What precautions should you take when taking Revumenib-Revuforj?

In the clinical study of Revumenib-Revuforj in the treatment of acute leukemia (including AML, ALL), researchers found some warnings and precautions that require special attention, including differentiation syndrome, QTc interval prolongation and embryo-fetal toxicity. These risks can have a significant impact on patient safety and treatment outcomes and must be taken seriously when using Revuforj.

1. Differentiation syndrome (DS)

Differentiation syndrome is a serious adverse reaction and the use of Revuforj may result in fatal or life-threatening DS. Characteristic symptoms of differentiation syndrome include fever, dyspnea, hypoxia, peripheral edema, pleuropericardial effusion, acute renal failure, and/or hypotension. The occurrence of these symptoms may indicate serious complications in the patient, so doctors should be highly vigilant.

Before starting treatment with Revuforjthe patient's white blood cell count (WBC) drops below 25 micrograms per liter (Gi/L) to reduce the risk of DS. If DS is suspected during treatment, systemic corticosteroid therapy needs to be initiated immediately. For example, for adult patients, dexamethasone 10 mg can be injected intravenously every 12 hours; while for children weighing less than 40 kg, dexamethasone 0.25 mg/kg/dose intravenously is recommended every 12 hours, and the treatment duration is at least 3 days until symptoms and signs disappear.

Of note, if a patient develops severe signs and/or symptoms that persist for more than 48 hours after systemic corticosteroid therapy, or develops life-threatening conditions (such as pulmonary symptoms requiring ventilator support), Revuforj should be discontinued immediately. At the same time, if differentiation syndrome recurs after tapering corticosteroids, steroids need to be reintroduced to control symptoms.

2.QTc interval prolongation

QTc interval prolongation is another important adverse reaction that may occur during treatment with Revuforj. This phenomenon can cause severe cardiac arrhythmias and even be life-threatening. Therefore, electrolyte abnormalities, including hypokalemia and hypomagnesemia, must be corrected before treatment and an electrocardiogram performed before starting Revuforj treatment. Treatment should not be initiated if the patient's QTcF exceeds 450 msec.

In the first four weeks of treatment, it is recommended to conduct an electrocardiogram at least once a week, and then at least once a month to detect changes in the QTc interval in a timely manner. Increased frequency of ECG monitoring may be necessary in patients with congenital long QTc syndrome, congestive heart failure, electrolyte abnormalities, or who are taking drugs known to prolong the QTc interval. When Revuforj is combined with drugs known to prolong the QTc interval, the risk of QTc interval prolongation may increase and should be treated with caution.

3. Embryo-Fetotoxicity

The use of Revuforj also requires special attention to its potential toxicity to the embryo and fetus. Based on animal testing results, Revuforj may cause harm to the fetus when taken by pregnant women. In an animal reproduction study, oral administration of Revuforj to pregnant rats resulted in adverse developmental outcomes including embryo-fetal death, malformations, and altered fetal growth. Maternal exposure was approximately 0.5 times the human exposure at the recommended dose.

Therefore, doctors should inform pregnant women before prescribing the drugof the possible risks to the fetus caused by the use of Revuforj, and recommend that all women and men of reproductive potential use effective contraception during treatment with Revuforj and for 4 months after the last dose to prevent potential harm to the fetus.

Reference materials:https://www.drugs.com/monograph/revumenib.html